Millipore Sigma Vibrant Logo

444967 MEK1/2 Inhibitor IV - CAS 212631-67-9 - Calbiochem

The MEK1/2 Inhibitor IV, also referenced under CAS 212631-67-9, controls the biological activity of MEK1/2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

MEK1/2 Inhibitor IV - CAS 212631-67-9 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromo-benzamide, PD184161, MEK Inhibitor IV

View This Product on Sigma-Aldrich
444967
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
212631-67-9C₁₇H₁₃BrClF₂IN₂O₂

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
444967-5MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 5 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable, blood-brain barrier permeant, and orally active hydroxamate compound that is reported to inhibit MEK activity (IC50 = 10-100 nM) without competing against ATP or Erk binding and exhibit excellent selectivity over 27 other cellular kinases, including JNK, MAPK2/ERK2, SAPK2a, SAPK2b, SAPK3, and SAPK4 (IC50 > 10 µM). Shown to be superior to PD 98059 (Cat. Nos. 513000 and 513001) and U0126 (Cat. No. 662005) in suppressing Erk1/2 phosphorylation in Hep3B, HepG2, PLC, and SKHep human liver cancer cells (IC50 <0.1 µM) in vitro and effectively reduce Erk1/2 phosphorylation in hippocampal tissue in mice (ED50 <50 mg/kg, i.p.) in vivo. Both PD184161 and U0126 are shown to induce necrosis of several types of glucose-deprived cells via an indirect action on the F0 component of the mitochondrial F1F0-ATPase/synthase.
      Catalogue Number444967
      Brand Family Calbiochem®
      Synonyms2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromo-benzamide, PD184161, MEK Inhibitor IV
      References
      ReferencesYip-Schneider, M.T., et al. 2009. J. Pharmacol. Exp. Ther. 329, 1063.
      Duman, C.H., et al. 2007. Biol. Psychiatry 61, 661.
      Klein, P.J., et al. 2006. Neoplasia 8, 1.
      Thottassery, J.V., et al. 2004. Cancer Res. 64, 4637.
      Yung, H.W., et al. 2004. Biochem. Pharmacol. 68, 351.
      Product Information
      CAS number212631-67-9
      FormWhite solid
      Hill FormulaC₁₇H₁₃BrClF₂IN₂O₂
      Chemical formulaC₁₇H₁₃BrClF₂IN₂O₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      444967-5MGCN 04055977204537

      Documentation

      MEK1/2 Inhibitor IV - CAS 212631-67-9 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      MEK1/2 Inhibitor IV - CAS 212631-67-9 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      444967

      参考資料

      参考資料の概要
      Yip-Schneider, M.T., et al. 2009. J. Pharmacol. Exp. Ther. 329, 1063.
      Duman, C.H., et al. 2007. Biol. Psychiatry 61, 661.
      Klein, P.J., et al. 2006. Neoplasia 8, 1.
      Thottassery, J.V., et al. 2004. Cancer Res. 64, 4637.
      Yung, H.W., et al. 2004. Biochem. Pharmacol. 68, 351.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-July-2010 RFH
      Synonyms2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromo-benzamide, PD184161, MEK Inhibitor IV
      DescriptionA cell-permeable, blood-brain barrier permeant, and orally active hydroxamate compound that is reported to inhibit MEK activity (IC50 = 10-100 nM) without competing against ATP or Erk binding and exhibit excellent selectivity over 27 other cellular kinases, including JNK, MAPK2/ERK2, SAPK2a, SAPK2b, SAPK3, and SAPK4 (IC50 > 10 µM). Shown to be superior to PD 98059 (Cat. Nos. 513000 and 513001 and U0126 (Cat. No. 662005) in suppressing Erk1/2 phosphorylation in Hep3B, HepG2, PLC, and SKHep human liver cancer cells (IC50 <0.1 µM) in vitro and effectively reduce Erk1/2 phosphorylation in hippocampal tissue in mice (ED50 <50 mg/kg, i.p.) in vivo. Both PD184161 and U0126 are shown to induce necrosis of several types of glucose-deprived cells via an indirect action on the F0 component of the mitochondrial F1F0-ATPase/synthase.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number212631-67-9
      Chemical formulaC₁₇H₁₃BrClF₂IN₂O₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (100 mg/ml) or Ethanol (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesYip-Schneider, M.T., et al. 2009. J. Pharmacol. Exp. Ther. 329, 1063.
      Duman, C.H., et al. 2007. Biol. Psychiatry 61, 661.
      Klein, P.J., et al. 2006. Neoplasia 8, 1.
      Thottassery, J.V., et al. 2004. Cancer Res. 64, 4637.
      Yung, H.W., et al. 2004. Biochem. Pharmacol. 68, 351.